Episode Details

Rubella (German Measles) and Congenital Rubella Syndrome

Rubella is a viral illness generally characterized by mild symptoms in children and adults but possessing devastating potential for developing fetuses. While endemic rubella was eliminated in the United States in 2004, maintaining high vaccination coverage remains critical to prevent reintroduction and protect pregnant women.

The Critical Risk: Congenital Rubella Syndrome (CRS)

The primary objective of rubella management is preventing Congenital Rubella Syndrome (CRS).

• Impact on Pregnancy: Infection during early pregnancy, especially the first 12 weeks, can lead to miscarriage, stillbirth, or severe birth defects.

• Severe Defects: CRS causes a constellation of permanent disabilities, including deafness, cataracts, congenital heart disease, intellectual disability, and liver damage.

• Viral Shedding: Unlike typical cases, infants born with CRS may shed the virus in bodily fluids for up to one year, making them highly contagious to unvaccinated contacts.

Clinical Presentation

Rubella is often mild and up to 50% of infections are subclinical (symptom-free), yet these individuals can still transmit the virus.

• Symptoms: The hallmark sign is a maculopapular rash that starts on the face and spreads downward, lasting about 3 days. Other symptoms include low-grade fever, swollen lymph nodes (lymphadenopathy), and mild pink eye.

• Adult Complications: While children recover quickly, up to 70% of infected women experience arthritis or joint pain (arthralgia), which can last up to a month.

• Transmission: The virus spreads via respiratory droplets. Individuals are contagious from 7 days before to 7 days after the rash appears.

Prevention and Vaccination

The most effective defense against rubella is the live, attenuated vaccine, available as MMR (Measles, Mumps, Rubella) or MMRV (including Varicella).

• Efficacy: A single dose produces immunity in at least 95% of people, conferring long-term protection.

• Schedule: The standard schedule requires two doses: the first at 12–15 months and the second at 4–6 years.

• Safety: The vaccine is safe; common side effects are mild fever or rash. Serious adverse events like febrile seizures are rare, and studies refute any link between the vaccine and autism.

Contraindications and Precautions

Because the vaccine contains a live virus, specific restrictions apply:

• Pregnancy: Vaccination is contraindicated during pregnancy due to theoretical risks to the fetus. Women should avoid becoming pregnant for 4 weeks after vaccination. However, accidental vaccination during pregnancy has not been shown to cause CRS in offspring.

• Immunocompromise: Persons with severe immunodeficiency or those on high-dose steroids should not receive the vaccine.

• Illness: Vaccination should be deferred for those with moderate or severe acute illness